Business Context and Reporting Period
Company: Actuate Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2026
Reporting Period: Single event date (May 11, 2026)
Business Context: The Company is an emerging growth company incorporated in Delaware, focused on the development of elraglusib. This filing reports a significant regulatory milestone regarding its clinical development program.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a regulatory event and does not include a financial statement or earnings update.
Material Changes
- Regulatory Milestone: The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for the Company.
- Clinical Progress: The clearance enables the Company to conduct a Phase 1/2 study for elraglusib.
- Strategic Update: The Company announced future plans to advance the elraglusib development program.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release and corporate presentation (Exhibits 99.1 and 99.2) detailing the FDA clearance and future development plans. The text of the 8-K itself does not contain specific forward-looking guidance, numerical targets, or detailed risk factors beyond the standard disclaimer that the information is not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific scope and design of the approved Phase 1/2 study for elraglusib in the attached press release (Exhibit 99.1).
- Review the updated corporate presentation (Exhibit 99.2) for details on the timeline and milestones of the elraglusib development program.
- Confirm the Company's current cash runway and funding status, as this filing does not disclose liquidity or capital requirements for the upcoming trial.
- Monitor subsequent filings for any updates on the initiation of the Phase 1/2 study.